Physician profile
Teresa M Monzon
NPI 1629298955
$268.16
in general payments reported to CMS, 2019-2025
4 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.35 · 2020: $33.89 · 2021: $21.75 · 2024: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58.84 · Entertainment: $34.24 · Food and Beverage: $25.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58.84 |
| Entertainment | $34.24 |
| Food and Beverage | $25.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biolase, INC. | $99.95 | 2019-2021 | |
| Straumann USA LLC | $83.93 | 2024 | |
| Nobel Biocare USA | $50.04 | 2019-2020 | |
| Keystone Dental INC. | $34.24 | 2024 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teresa Monzon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.